View Older Stories
-
Q3 Preview: Johnson & Johnson (JNJ) Kicks Off Pharma Earnings; May Face Headwinds from FX, Generics
-
Deutsche Bank Cuts Price Target In MedTech
-
Notable Mergers and Acquisitions of the Day 09/29: (HGIC) (NUVA) (MRK)/(JNJ)
-
After-Hours Movers 09/28: (TWI) (THO) (ATO) (HPQ) Higher; (BDSI) (AMD) (WOR) (MOS) Lower
-
Kaufman Bros. Starts Boston Scientific (BSX) at Hold; Progress Made, But Remains a Turnaround, with Tough Growth Outlook
-
Find Saftey in These Top Dividend Aristocrats in This Crappy Market
-
Top 10 News Items 7/18-7/22: Apple Smashes Q3 Estimates; Express Scripts to Buy Medco in $29.1B Deal; Earnings Season Coming In Hot
-
Highlights From JNJ's Q2 Conference Call: Worldwide Sales Increased 8.3%; Net Earnings Up 4.9%
-
JNJ (JNJ) Makes Investors Think Following Q2 Beat as FY11 Outlook Maintained
-
Deutsche Bank Starts Johnson & Johnson (JNJ) at Hold; Some Upside But Mot Enough
-
Brean Murray Carret & Co. Starts Johnson & Johnson (JNJ) at Buy, $77 Price Target
-
Johnson & Johnson (JNJ) To Cut 900-1000 Jobs, Expects $500-$600 Million Special Charge Following Cordis Restructuring
-
Brean Murray Carret & Co. Starts Johnson & Johnson (JNJ) at Buy
-
First Global Upgrades Johnson & Johnson (JNJ) to Moderate Outperform; Revitalised Pharma Pipeline & Aggressive New Product Launch
-
UPDATE - GARP Research Initiates Coverage on Conceptus (CPTS) with a Buy; Very Compelling Valuation
-
Notable 52-Week Highs and Lows of the Day 05/12: (SYMC) (QCOR) (TJX) High; (CLWR) (PNSN) (HEV) Low
-
Notable 52-Week Highs and Lows of the Day 05/11: (TISA) (M) (LVLT) High; (ALTH) (HEV) (MTSN) Low
-
Goldman Sachs Upgrades Johnson & Johnson (JNJ) to Buy; Best New Product Story In Pharma
-
Notable Mergers and Acquisitions of the Day 04/27: (CTL)/(SVVS) (JNJ) (URS)
-
Johnson & Johnson (JNJ) to Acquire Synthes in $19.3B Deal
-
Corporate Earnings for Q1 Look Promising So Far, Here's the Top Movers...
-
Top 10 News Items 4/18-4/21: S&P Revises Outlook on US Credit Rating to Negative; Apple Posts Yet Another Blowout Quarter; Gold Crosses $1,500, Silver Over $46
-
Barclays Maintains an 'Overweight' on Abbott Labs (ABT); Q1 Review: Diversified Business and Consistent Growth Under-Appreciated
-
Highlights From JNJ's Q1 Conference Call: U.S. Sales Declined by 0.6%; Total Worldwide Revenues Increased 3.5%
-
Johnson & Johnson (JNJ) Issues Q1 'Beat-and-Raise' Led By Pharma Business
-
Notable Mergers and Acquisitions of the Day 04/18: (CYH)/(THC) (AMED) (JNJ)
-
Canaccord Genuity on Immucor (BLUD): BLUD-y good!
-
Q1 Earnings Season to Begin April 11th as Alcoa (AA) Leads the Way
-
Oppenheimer Recommends Large Cap Stocks for 2011; Sees Solid Outperformance Versus Small Cap (WMT, JNJ, KO, more)
-
First Global Downgrades Johnson & Johnson (JNJ) to Market Perform; Delay in Resolution of McNeil Recall/OTC Issues & Increased Generic Competition
-
Top 10 News Items 1/24-1/28: Violence in Egypt Impacts Stocks; Amazon, Ford Results Disappoint Investors
-
Notable ETF Movers of the Day 01/25: EWJ, UUP VXX Higher; UNG, GLD, MOO Lower
-
Johnson & Johnson (JNJ) Q4 Profit Drops 12% on Numerous Recalls
-
Trading Radar for 01/25: Verizon (VZ), 3M (MMM), Yahoo! (YHOO), RF Micro (RFMD), Juniper Networks (JNPR), Altera (ALTR) Report
-
Q4 Preview: Johnson & Johnson (JNJ) Looks for Cure to the Recall Blues
-
Barclays on U.S. Major Pharmaceuticals: U.S. Major Pharma 2011 Outlook: A View Beyond the Cliff
-
Morning Movers 01/10: GENE, ACAD, RPC, LDK, PLA, PSTI, CNXT, HILL, AUXL Higher; STRA, EDMC, DV, CPLA, ESI, PDLI Lower
-
Barclays on Medical Supplies & Devices: 3Q Ortho Update
-
Top 10 News Items for 10/18-10/22: Bank Concerns Remain Amid BofA's Bondholder Suit, Apple Still Top Dog, China Raises 1-Year Rates
-
Johnson & Johnson (JNJ) Q3 Earnings Beat; Raises FY10 Guidance
-
Trading Radar for 10/19: Goldman Sachs (GS), Yahoo! (YHOO), Bank of America (BAC), EMC (EMC) Report
